Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Rhea-AI Summary

Argus Mar 30 session

+1.30% close to close Open Argus

Details

News Market Reaction – SLNO

On Mar 30, the first trading day after this news, SLNO closed 1.30% above the previous close.

Data tracked by StockTitan Argus for the Mar 30 session.

Market Context

This announcement highlights a securities class action focused on Soleno’s disclosures around its Ph...

Analysis

This announcement highlights a securities class action focused on Soleno’s disclosures around its Phase 3 DCCR program and potential safety concerns in Prader‑Willi syndrome. The case covers trades between March 26, 2025 and November 4, 2025, with a May 5, 2026 deadline to seek lead-plaintiff status. In context of prior lawsuit headlines and recent corporate developments, investors may monitor legal progress, regulatory responses, and any updates on DCCR’s safety profile and commercial outlook.

Key Figures

Lead plaintiff deadline: May 5, 2026 Class period start: March 26, 2025 Class period end: November 4, 2025 +2 more

Lead plaintiff deadline

May 5, 2026

Deadline to request Court appointment as lead plaintiff

Class period start

March 26, 2025

Start of alleged securities fraud class period

Class period end

November 4, 2025

End of alleged securities fraud class period

Toll-free contact number

1-877-515-1850

Investor contact number for Kahn Swick & Foti

Case number

26-cv-01979

City of Pontiac Police and Fire Retirement System v. Soleno case

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Litigation announcement

   24h Move

   -5.9%

   Lawsuit alleging sham clinical trials and investor losses.

2. Feb 26

   Management change

   24h Move

   -7.1%

   CFO retirement and appointment of new chief financial officer.

3. Feb 25

   Earnings and launch

   24h Move

   -7.1%

   Profitable 2025 results and detailed VYKAT XR launch metrics.

4. Feb 11

   Earnings date set

   24h Move

   -1.1%

   Announcement of date and time for Q4 and full-year 2025 results.

5. Jan 29

   Conference participation

   24h Move

   -2.5%

   Plans to present at multiple investor healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

securities fraud, class action, phase 3, clinical trial, +2 more

6 terms

securities fraud financial

"investors of Soleno Therapeutics who were adversely affected by alleged securities fraud"

Securities fraud is the illegal act of lying to or misleading investors about the true value or prospects of stocks, bonds or other traded financial instruments — for example by making false statements, hiding key facts, trading on secret information, or artificially moving prices. It matters to investors because it can cause sudden losses, distort fair market prices and undermine trust in markets; think of it as someone rigging a scoreboard so others place bets on the wrong team.

View in glossary

class action regulatory

"notifies investors in Soleno Therapeutics, Inc. ... of a class action securities lawsuit"

A class action is a lawsuit where a group of people with similar complaints sue a company together instead of each person filing separately; think of it as a neighborhood banding together to take one case to court rather than everyone hiring separate lawyers. Investors care because class actions can lead to large settlements or judgments, damage a company’s reputation, drain cash reserves, and distract management — all of which can reduce a company’s stock value and affect future earnings.

phase 3 medical

"The Phase 3 clinical trial program for DCCR, the Company's only commercial product"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

clinical trial medical

"The Phase 3 clinical trial program for DCCR, the Company's only commercial product"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

hyperphagia medical

"for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome"

An abnormally strong, persistent urge to eat that leads to excessive food intake beyond normal hunger; it can be a symptom of neurological, hormonal, genetic, or psychiatric conditions. Investors care because therapies that reduce hyperphagia can become measurable drug trial endpoints, define patient populations and market size, and influence regulatory approval, reimbursement prospects and commercial potential in the obesity and rare-disease sectors.

prader-willi syndrome medical

"for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome or "PWS""

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqcm-slno/

Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.

CASE DETAILS: According to the Complaint, Soleno and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) The Phase 3 clinical trial program for DCCR, the Company's only commercial product (for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome or "PWS"), systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its administration, including indications of excessive fluid retention among clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by the Company; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

The case is City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979.

WHAT TO DO? If you invested in Soleno and suffered a loss during the relevant time frame, you have until May 5, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302727698.html

SOURCE Kahn Swick & Foti, LLC